# Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

> **NCT03795428** · PHASE2 · TERMINATED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 25 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Pemziviptadil (PB1046) Injection

## Key facts

- **NCT ID:** NCT03795428
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-10
- **Primary completion:** 2022-01-11
- **Final completion:** 2022-01-11
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Terminated: Study drug resupply delayed (Covid-19)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03795428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03795428, "Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03795428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*